Drugs / MIDRIXNEO-LUNG
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04078269 | Aug 2019 → Feb 2024 | non-small cell lung carcinoma | University Hospital, Ghent | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MIDRIXNEO-LUNG | “Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks” NCT04078269 ↗ |
| Modality | Cell therapy | “MIDRIXNEO-LUNG is a novel autologous dendritic cell vaccine” NCT04078269 ↗ |
| Route | Intravenous | “Intravenous infusions of MIDRIXNEO-LUNG DCs every 2 weeks” NCT04078269 ↗ |